{
    "2019-11-12": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Supernus Pharmaceuticals seeks FDA approval for ADHD drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "approval",
                        "ADHD",
                        "drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance速 in people hospitalized for acute heart failure who have been stabilized",
                "features": {
                    "keywords": [
                        "Boehringer Ingelheim",
                        "Lilly",
                        "Jardiance",
                        "study",
                        "acute heart failure"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-11-08",
                "original_text": "ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz速 (ixekizumab) Versus Humira速 (adalimumab) Trial in Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "ACR",
                        "Lilly",
                        "Taltz",
                        "Humira",
                        "Psoriatic Arthritis",
                        "trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-11-08",
                "original_text": "ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz速 (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
                "features": {
                    "keywords": [
                        "ACR",
                        "Lilly",
                        "Taltz",
                        "COAST-X",
                        "Phase 3",
                        "Non-Radiographic Axial Spondyloarthritis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}